Value proposition

Creating breakthrough therapies. Changing lives.

Antion Biosciences SA (Antion) is a Swiss biopharmaceutical company developing novel gene and gene-modified cell therapies to treat and cure diseases with significant unmet medical needs. Our proprietary technologies allow for the creation of multimodal treatments that aim to substantially enhance clinical safety and efficacy.

We have a number of products in preclinical development, and it is our mission to translate our proprietary technologies into meaningful therapies for the benefit of patients. We are fully committed to creating high-value therapeutic assets, while developing strategies to ensure broad accessibility of our treatments, especially to resource poor communities.

Our patent-protected technologies are versatile, highly effective and broadly applicable to various therapeutic areas. We believe that these technologies will allow us to create both first-in-class and best-in-class therapies. We recognize that strengthening our IP portfolio is central to the commercial success of Antion, and strive to enhance and protect our core technologies further. We actively explore collaborations and partnering opportunities to out-license our proprietary technologies and in-license novel technologies that are commercially important to us.

Antion is founded by a team of leading researchers, entrepreneurs and financial executives. Our founders and researchers are recognized scientists and clinicians from the Universities of Geneva, Zurich and Pretoria, with proven track records in molecular medicine and gene engineering. The team has a long collaborative history and previous success in establishing other biotech ventures. Antion’s executive team has broad experience in financial administration, trading, fundraising, initial public offerings, and mergers and acquisitions.

Gene engineering, Cell therapy, HIV cure, Cancer immunotherapy, Sensory disorders, and Next Generation CAR T cells